Abstract: The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.

Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.

Abstract: The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.

Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.

Abstract: The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.

Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.

Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.

Abstract: The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.

Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.

Abstract: The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.

Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.

Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.

Abstract: An embodiment of the disclosed method and apparatus relates to a system for detecting a rub in a turbomachine. The system comprises: a turbomachine; sensors monitoring turbomachine conditions; and an on site monitor in communication with the sensors, and loaded with instructions to implement a method for detecting a rub in the turbomachine. An embodiment of the disclosed method relates to a method for detecting a rub in a turbomachine, the method comprising: monitoring turbomachine conditions; and determining whether a rub is occurring. Another embodiment of the disclosed apparatus relates to a storage medium encoded with a machine-readable computer program code for detecting a rub in a turbomachine, the storage medium including instructions for causing a computer to implement a method. The method comprises: obtaining data indicating turbomachine conditions; and determining whether a rub is occurring.

Abstract: A hemorrhoid relief and anal hygiene device includes a pressure member for placement between opposing buttock surfaces in the natal cleft adjacent to the anus of the user. The pressure member has opposite side faces for each positioning against one of the opposing buttock surfaces of the user. The pressure member has a perimeter wall extending between the opposite side faces with first, second, and third sections. The first and second sections have inboard ends converging at a protruding crest for partial insertion in the anus. The first and second sections are concave for abutting opposite areas of the surface of the anus. The third section extends between outboard ends of the first and second sections. A second embodiment of the device includes a bulbous central portion having a substantially spherical shape and a pair of elongate side members extending outwardly from opposite sides of the central portion.

Abstract: A hemorrhoid relief and anal hygiene device is provided including a pressure member for placement between opposing buttock surfaces in the natal cleft adjacent to the anus of the user. The pressure member has opposite side faces for each positioning against one of the opposing buttock surfaces of the user. Each of the side faces of the pressure member is substantially planar. Each of the side faces of the pressure member lie in substantially parallel planes. The pressure member has a perimeter wall that extends between the opposite side faces. The perimeter wall has a first section, a second section, and a third section. The first and second sections of the perimeter wall has inboard ends converging at a protruding crest adapted for partial insertion in the anus of the user. The first and second sections are concave for abutting opposite areas of the surface of the anus. The third section extends between outboard ends of the first and second sections.